secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0001493152-23-019186
Event type: regulatory
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharmaceuticals Regains Nasdaq Compliance After Late Filing, Provides Pipeline Update
--------------------------------------------------------------------------------

- Received delisting notice from Nasdaq on May 24 for failure to timely file Form 10-Q, but filed on May 25 and regained compliance.
- Closed private placement of $4.3M secured convertible note and warrants for $4.0M investment.
- Expects final submission to FDA for Phase II trial of Ropidoxuridine in glioblastoma by end of Q2 2023.
- Awarded U.S. Patent No. 11,654,157 for cancer therapies combining halogenated thymidines and thymidine phosphorylase inhibitors with radiation.
- Appointed Dr. Bette Jacobs as independent director to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315223019186/0001493152-23-019186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315223019186/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-019186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer